SEC Company Response from Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI) — Nov 29, 2016
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: Nov. 29, 2016 · CIK: 0001503802 · Accession: 0001193125-16-779466
AI Filing Summary & Sentiment
File numbers found in text: 333-214489
Show Raw Text
CORRESP 1 filename1.htm CORRESP KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE, SECOND FLOOR NEWTON, MA 02459 November 29, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-3 File No. 333-214489 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-214489) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on December 1, 2016, or as soon thereafter as practicable. Very truly yours, Karyopharm Therapeutics Inc. By: /s/ Christopher B. Primiano Name: Christopher B. Primiano Title: Senior Vice President, Corporate Development, General Counsel and Secretary